Manuel Grimaldi

883 total citations
7 papers, 695 citations indexed

About

Manuel Grimaldi is a scholar working on Oncology, Pathology and Forensic Medicine and Dermatology. According to data from OpenAlex, Manuel Grimaldi has authored 7 papers receiving a total of 695 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Pathology and Forensic Medicine and 2 papers in Dermatology. Recurrent topics in Manuel Grimaldi's work include Lymphoma Diagnosis and Treatment (3 papers), Neutropenia and Cancer Infections (2 papers) and Viral-associated cancers and disorders (2 papers). Manuel Grimaldi is often cited by papers focused on Lymphoma Diagnosis and Treatment (3 papers), Neutropenia and Cancer Infections (2 papers) and Viral-associated cancers and disorders (2 papers). Manuel Grimaldi collaborates with scholars based in United States. Manuel Grimaldi's co-authors include John D. Hainsworth, F. Anthony Greco, Sharlene Litchy, Don W. Shaffer, Rafael Bornstein, Norman Wolmark, Vincent Caggiano, Howard A. Burris, Bernard Fisher and Edward H. Romond and has published in prestigious journals such as Journal of Clinical Oncology and Cancer.

In The Last Decade

Manuel Grimaldi

7 papers receiving 662 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Manuel Grimaldi United States	6	494	323	243	161	78	7	695
L. E. Shepherd Canada	15	534 1.1×	185 0.6×	307 1.3×	52 0.3×	184 2.4×	43	800
J. Kalmus Germany	10	708 1.4×	360 1.1×	114 0.5×	99 0.6×	294 3.8×	22	1.0k
Ellen Chase United States	4	406 0.8×	652 2.0×	65 0.3×	140 0.9×	118 1.5×	7	756
Brendan Rooney United Kingdom	10	244 0.5×	249 0.8×	89 0.4×	141 0.9×	295 3.8×	21	593
Andrea Knapp Switzerland	15	437 0.9×	553 1.7×	31 0.1×	179 1.1×	58 0.7×	45	731
Susan Hunter United States	12	406 0.8×	429 1.3×	148 0.6×	41 0.3×	187 2.4×	16	662
R. Basser Australia	15	397 0.8×	49 0.2×	115 0.5×	54 0.3×	179 2.3×	31	731
Coralie Poncet France	14	117 0.2×	112 0.3×	131 0.5×	93 0.6×	63 0.8×	55	526
Nina Keldsen Denmark	13	373 0.8×	123 0.4×	91 0.4×	43 0.3×	135 1.7×	31	602
Paul T. Adams United States	10	435 0.9×	63 0.2×	275 1.1×	21 0.1×	115 1.5×	15	611

Countries citing papers authored by Manuel Grimaldi

Since Specialization

Citations

This map shows the geographic impact of Manuel Grimaldi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Grimaldi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Grimaldi more than expected).

Fields of papers citing papers by Manuel Grimaldi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuel Grimaldi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Grimaldi. The network helps show where Manuel Grimaldi may publish in the future.

Co-authorship network of co-authors of Manuel Grimaldi

This figure shows the co-authorship network connecting the top 25 collaborators of Manuel Grimaldi. A scholar is included among the top collaborators of Manuel Grimaldi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuel Grimaldi. Manuel Grimaldi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Hainsworth, John D., et al.. (2005). Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 23(6). 1088–1095. 253 indexed citations

Liggett, William H., John D. Hainsworth, David R. Spigel, et al.. (2005). Fludarabine/rituximab (FR) followed by alemtuzumab as first-line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): A Minnie Pearl Cancer Research Network phase II trial. Journal of Clinical Oncology. 23(16_suppl). 6556–6556. 3 indexed citations

Hainsworth, John D., Sharlene Litchy, Lisa H. Morrissey, et al.. (2005). Rituximab Plus Short-Duration Chemotherapy As First-Line Treatment for Follicular Non-Hodgkin’s Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 23(7). 1500–1506. 33 indexed citations

Hainsworth, John D., Howard A. Burris, Denise A. Yardley, et al.. (2001). Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial. Journal of Clinical Oncology. 19(15). 3500–3505. 132 indexed citations

Fisher, Bernard, Stewart Anderson, D. Lawrence Wickerham, et al.. (1997). Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.. Journal of Clinical Oncology. 15(5). 1858–1869. 240 indexed citations

Broghamer, Walter L., Kenneth P. McConnell, Manuel Grimaldi, & A. J. Blotcky. (1978). Serum selenium and reticuloendothelial tumors. Cancer. 41(4). 1462–1466. 29 indexed citations

Liu, Yong K., et al.. (1978). Myelopoietic abnormalities in patients with metastatic carcinoma. Cancer. 41(3). 1193–1198. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact